Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw

Y. H. Cha, N. Hong, Y. Rhee, I. H. Cha

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Although osteoradionecrosis (ORN) is a serious complication of craniofacial radiotherapy, the current management methods remain suboptimal. Teriparatide (TPTD), a recombinant human parathyroid hormone (1–34), has shown beneficial effects on osseous regeneration in medication-related osteonecrosis of the jaw or periodontitis. However, TPTD therapy in irradiated bones has not been indicated yet because of the theoretical risk of osteosarcoma seen in rat models. Hence, we first report here two patients with tongue cancer with late-emerging ORN who were successfully treated with TPTD for 4–6 months with serum calcium and vitamin D supplementation. In contrast to the usual progress of ORN, the bone defect regenerated well and bone turnover markers including serum C-terminal telopeptide of type 1 collagen and osteocalcin were restored with TPTD therapy. Our experience might suggest that TPTD therapy with careful monitoring can provide an effective treatment option for patients with ORN in select refractory cases, with the benefits outweighing the potential risks.

Original languageEnglish
Pages (from-to)987-992
Number of pages6
JournalOsteoporosis International
Volume29
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Osteoradionecrosis
Teriparatide
Jaw
Tongue Neoplasms
Therapeutics
Bone and Bones
Osteonecrosis
Bone Remodeling
Periodontitis
Osteocalcin
Osteosarcoma
Collagen Type I
Vitamin D
Regeneration
Radiotherapy
Biomarkers
Calcium
Serum

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{af494048c5314893954ca7533ba08dcf,
title = "Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw",
abstract = "Although osteoradionecrosis (ORN) is a serious complication of craniofacial radiotherapy, the current management methods remain suboptimal. Teriparatide (TPTD), a recombinant human parathyroid hormone (1–34), has shown beneficial effects on osseous regeneration in medication-related osteonecrosis of the jaw or periodontitis. However, TPTD therapy in irradiated bones has not been indicated yet because of the theoretical risk of osteosarcoma seen in rat models. Hence, we first report here two patients with tongue cancer with late-emerging ORN who were successfully treated with TPTD for 4–6 months with serum calcium and vitamin D supplementation. In contrast to the usual progress of ORN, the bone defect regenerated well and bone turnover markers including serum C-terminal telopeptide of type 1 collagen and osteocalcin were restored with TPTD therapy. Our experience might suggest that TPTD therapy with careful monitoring can provide an effective treatment option for patients with ORN in select refractory cases, with the benefits outweighing the potential risks.",
author = "Cha, {Y. H.} and N. Hong and Y. Rhee and Cha, {I. H.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s00198-017-4343-2",
language = "English",
volume = "29",
pages = "987--992",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "4",

}

Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw. / Cha, Y. H.; Hong, N.; Rhee, Y.; Cha, I. H.

In: Osteoporosis International, Vol. 29, No. 4, 01.04.2018, p. 987-992.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw

AU - Cha, Y. H.

AU - Hong, N.

AU - Rhee, Y.

AU - Cha, I. H.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Although osteoradionecrosis (ORN) is a serious complication of craniofacial radiotherapy, the current management methods remain suboptimal. Teriparatide (TPTD), a recombinant human parathyroid hormone (1–34), has shown beneficial effects on osseous regeneration in medication-related osteonecrosis of the jaw or periodontitis. However, TPTD therapy in irradiated bones has not been indicated yet because of the theoretical risk of osteosarcoma seen in rat models. Hence, we first report here two patients with tongue cancer with late-emerging ORN who were successfully treated with TPTD for 4–6 months with serum calcium and vitamin D supplementation. In contrast to the usual progress of ORN, the bone defect regenerated well and bone turnover markers including serum C-terminal telopeptide of type 1 collagen and osteocalcin were restored with TPTD therapy. Our experience might suggest that TPTD therapy with careful monitoring can provide an effective treatment option for patients with ORN in select refractory cases, with the benefits outweighing the potential risks.

AB - Although osteoradionecrosis (ORN) is a serious complication of craniofacial radiotherapy, the current management methods remain suboptimal. Teriparatide (TPTD), a recombinant human parathyroid hormone (1–34), has shown beneficial effects on osseous regeneration in medication-related osteonecrosis of the jaw or periodontitis. However, TPTD therapy in irradiated bones has not been indicated yet because of the theoretical risk of osteosarcoma seen in rat models. Hence, we first report here two patients with tongue cancer with late-emerging ORN who were successfully treated with TPTD for 4–6 months with serum calcium and vitamin D supplementation. In contrast to the usual progress of ORN, the bone defect regenerated well and bone turnover markers including serum C-terminal telopeptide of type 1 collagen and osteocalcin were restored with TPTD therapy. Our experience might suggest that TPTD therapy with careful monitoring can provide an effective treatment option for patients with ORN in select refractory cases, with the benefits outweighing the potential risks.

UR - http://www.scopus.com/inward/record.url?scp=85038109985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038109985&partnerID=8YFLogxK

U2 - 10.1007/s00198-017-4343-2

DO - 10.1007/s00198-017-4343-2

M3 - Article

C2 - 29249017

AN - SCOPUS:85038109985

VL - 29

SP - 987

EP - 992

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 4

ER -